StockProfiler.US: Stock Profiler.US: Stock Watch: ETEC, SNRY, IMUC, ETLO

Emtec, Inc. (OTCBB:ETEC); Solar Energy Initiatives, Inc. (OTCBB: SNRY); ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC); Etelos, Inc. (OTCBB:ETLO)

StockProfiler.US is Introducing Leading Microcap Companies! We welcome Investors to sign up and subscribe to our FREE Newsletter at www.stockprofiler.us. Please follow our thread on www.twitter.com at StockProfilerUS

-------------------------------------------

Emtec, Inc. closed at $0.70 Wednesday, trading 10,000 shares.

Company News- October 22, 2009: Emtec, Inc. Expands Healthcare Offerings Through New Partnerships With BridgeHead and FairWarning

Emtec, Inc. (OTCBB:ETEC) announced earlier today the expansion of its healthcare offerings through two new partnerships - FairWarning , a supplier of cross-platform healthcare privacy surveillance solutions, and BridgeHead Software, a leading provider of Healthcare Data Management (HDM) software for healthcare institutions worldwide. These partnerships provide Emtec clients innovative solutions to help meet compliance, security and Health Insurance Portability and Accountability Act (HIPAA) requirements associated with electronic health record (EHR) implementation.

To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.

About Emtec, Inc.

Emtec, Inc. established in 1964, is a systems integrator, providing services and products to the federal, state, local, education and commercial markets. Emtec operates two business segments: Emtec Infrastructure Services and Emtec Global Services. Emtec's Infrastructure Services Division provides IT transformation & optimization consulting, business service management, enterprise architecture, data management and integration services. Emtec Global Services expertise includes software development, software consulting, business analysis, quality assurance, and testing. For more information visit www.emtecinc.com.

-------------------------------------------

Solar Energy Initiatives, Inc. closed at $0.37 Wednesday, trading 19,700 shares.

Company News- October 22, 2009: Solar Energy Initiatives, Inc. Yields Immediate Gains after Realigning its Dealer Operations

Solar Energy Initiatives, Inc. (OTCBB: SNRY) executing on its corporate mission to Renew The Nation, creating economic development through the sale and installation of Solar Thermal, Photovoltaic (PV) and other Solar technologies, earlier today it announced immediate results following the reorganization of its Dealer Operations.

To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.

About Solar Energy Initiatives, Inc.

Solar Energy Initiatives, Inc. (www.SolarEnergy.com) is executing its "RENEW THE NATION" campaign, intended to promote job growth nationwide via an aggressive grass roots effort. The main focus of RENEW THE NATION will be working with companies in the construction industry and related trades affected by the economic downturn to re-train and re-deploy their workforce into solar dealers, allowing this important national asset to meet the needs of the Solar Energy industry, the fastest growing industry in the world. We are executing on a multi-pronged approach to achieve our plan. This includes: continuing development of one of the fastest growing dealer networks in the U.S. that sells and installs solar solutions to homeowners and commercial customers; solar education and technical training to the private and public sectors, placing solar systems on large commercial buildings and selling the energy output to the owner/occupant(s) through Solar Power Purchase Agreements (PPAs); and becoming a developer of solar parks bringing together landowners, utilities and our corporate resources to build large photovoltaic installations.

-------------------------------------------

ImmunoCellular Therapeutics, Ltd. closed at $1.07 Wednesday, trading 38,095 shares.

Company News- October 22, 2009: ImmunoCellular Therapeutics Engages Dr. Peter Brooks of the Maine Medical Center to Explore Cancer Stem Cell Targets

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) announced earlier today that it has signed a research agreement with Dr. Peter Brooks of the Maine Medical Center, a specialist in the mechanisms that regulate angiogenesis, tumor growth and metastasis, to explore novel targets and antibodies associated with targeting cancer stem cells (CSCs). The collaboration is designed to produce novel antibodies using the Company's proprietary CSCs isolated from glioblastoma patients to target epitopes primarily present on CSCs. This could enhance the understanding of the expression and function of molecular signatures in CSCs that might help to better define them, potentially enabling more effective approaches for identifying and treating a wide range of malignant human tumors.

To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The company's "off the shelf" therapeutic vaccine product candidate targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials for glioblastoma during the first quarter of 2010. IMUC also recently completed a Phase I trial of its dendritic cell-based clinical product candidate for glioblastoma. IMUC has entered into a research and license option deal with the Roche Group for one of its monoclonal antibodies for the diagnosis and treatment of ovarian cancer and multiple myeloma, that provides for potential licensing and milestone payments of $32MM and royalties if the Roche Group exercises its option and commercializes this antibody technology for multiple indications. IMUC is in pre-clinical development of another monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer, and is also evaluating its platform technology for monoclonal antibody discovery using differential immunization for diagnosing and treating multiple types of cancer. To learn more about IMUC, please visit www.imuc.com.

-------------------------------------------

Etelos, Inc. closed at $0.73 Wednesday, trading 17,400 shares.

Company News- October 22, 2009: Egnyte Becomes Etelos Syndication Partner

Etelos, Inc. (OTCBB:ETLO), a developer and operator of private labeled Marketplaces for Web-based business applications, announced earlier today that Egnyte, a leading provider of on-demand file server solutions, has become an Etelos Syndication Partner.

To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.

About Etelos, Inc.

Etelos is the developer of a Web app distribution platform for delivering Web apps for businesses. Unlike other cloud computing and Platform-as-a-Service (PaaS) solutions, Etelos enables software manufacturers to migrate existing applications or to create new applications, then to package, distribute, host, bill, market and support their Software-as-a-Service (SaaS) enabled applications through a number of third-party branded application marketplaces, all based on the Etelos Platform Suite. Etelos, the Etelos Platform Suite, EASE, Etelos App Server, Etelos VE, Etelos Cloud and Etelos Marketplace are trademarks of Etelos, Inc.; other trademarks are the property of their respective owners. For more information about Etelos, please visit Etelos.com.

-------------------------------------------

The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Stock Profiler.US, LLC's News Division includes but is not limited to: www.stockprofiler.us; www.associatesfortune.com; www.fastmoneytalk.com; www.markettelegraph.com; www.thewallstreetleader.com; and www.daytradersdigest.com. Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers and terms of use, go to www.stockprofiler.us.

Keywords: Small Cap Investments, Investor Relations, I/R Services, Investment Tools, Stock Profiles, Stock Market Quotes, Media Coverage, Google Finance, Google Analytics, Google, Yahoo Finance, Yahoo, MSNBC, Search Engine, AOL Finance, AOL, Businesswire, PR Newswire Alphatrade, Comtex, Comtex A, Comtex B, Zacks, Real Trader, Market News Publications, AFX U.K., Future World, JAGNotes.com, Internetwire, EURO PR News, First Call, PrimeZone, U.S. News, Forbes, Track Notes

CONTACT: StockProfiler.US Tel: +1 603 424 4420 e-mail: info@stockprofiler.us WWW: http://www.stockprofiler.us

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: advisor, broker, business, cancer, clinical, commercial, consulting, corporate, dealer, education, e-mail, energy, euro, finance, health, healthcare, insurance, investment, investment opinion, knowledge management, market, media, medical, products, research, securities, security, small cap, software, solar power, technology, track, training, trial, utilities, vaccine, web